Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a supplement combo recharge Alzheimer's brains?

NCT ID NCT04740580

Symptom relief Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers at Baylor College of Medicine are testing whether a supplement combination called GlyNAC can improve brain energy use and reduce inflammation in people with Alzheimer's disease. The trial enrolls 52 adults aged 55 to 85 who have progressive memory loss and amyloid plaques in the brain. Participants receive either GlyNAC or a placebo supplement called alanine, and researchers measure changes in cognition, brain glucose uptake, and brain inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a supplement combination of glycine and N-acetylcysteine (GlyNAC)
What this could lead to
If it works, this could point toward a low-cost supplement that supports brain energy and reduces inflammation in Alzheimer's disease.
What could go wrong
This is a very early, small trial with 52 participants. Supplements may not reach the brain in useful amounts, and any cognitive benefit could be modest or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 55-85 years; * Gradual and progressive memory loss for more than 1 year, with a Montreal Cognitive Assessment score of 10-20; * Amyloid positivity on PET scan; * Availability of a study partner. Exclusion Criteria: * hospitalization in past 3 months; * use of insulin medications; * untreated thyroid disease; * creatinine levels \>1.5 mg/dL; * hemoglobin concentration \<11.0 g/dL; * known liver disease, or AST/ALT level \>2x ULN; * history of stroke, brain tumor, active heart failure or active cancer (removable basal cell cancers will not be an exclusion criteria); * untreated depression or other severe psychiatric disorders; * pregnancy or nursing (unlikely in this population)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.